Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition

Cárdenas-Rodríguez N., Ignacio-Mejía I., Correa-Basurto J., Carrasco-Vargas H., Vargas-Hernández MA., Albores-Méndez EM.

Clinical Trial on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38612615
PMCID
PMC11012123
DOI
10.3390/ijms25073805
Citations
7

Abstract (original English)

The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and treatment is crucial. Neuroinflammation causes the most common manifestations of this disease including headaches, fatigue, insomnia, depression, anxiety, among others. Currently, there are no specific management proposals; however, given that the inflammatory component involves cytokines and free radicals, these conditions must be treated to reduce the current symptoms and provide neuroprotection to reduce the risk of a long-term neurodegenerative disease. It has been shown that cannabis has compounds with immunomodulatory and antioxidant functions in other pathologies. Therefore, exploring this approach could provide a viable therapeutic option for PCC, which is the purpose of this review. This review involved an exhaustive search in specialized databases including PubMed, PubChem, ProQuest, EBSCO, Scopus, Science Direct, Web of Science, and Clinical Trials. Phytocannabinoids, including cannabidiol (CBD), cannabigerol (CBG), and Delta-9-tetrahydrocannabinol (THC), exhibit significant antioxidative and anti-inflammatory properties and have been shown to be an effective treatment for neuroinflammatory conditions. These compounds could be promising adjuvants for PCC alone or in combination with other antioxidants or therapies. PCC presents significant challenges

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansCannabisNeurodegenerative DiseasesHallucinogensAntioxidantsCannabinoid Receptor AgonistsCOVID-19Neuroinflammatory DiseasesPost-Acute COVID-19 Syndrome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research